» Articles » PMID: 38791899

Updates on the Management of Colorectal Cancer in Older Adults

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 May 25
PMID 38791899
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) poses a significant global health challenge. Notably, the risk of CRC escalates with age, with the majority of cases occurring in those over the age of 65. Despite recent progress in tailoring treatments for early and advanced CRC, there is a lack of prospective data to guide the management of older patients, who are frequently underrepresented in clinical trials. This article reviews the contemporary landscape of managing older individuals with CRC, highlighting recent advancements and persisting challenges. The role of comprehensive geriatric assessment is explored. Opportunities for treatment escalation/de-escalation, with consideration of the older adult's fitness level. are reviewed in the neoadjuvant, surgical, adjuvant, and metastatic settings of colon and rectal cancers. Immunotherapy is shown to be an effective treatment option in older adults who have CRC with microsatellite instability. Promising new technologies such as circulating tumor DNA and recent phase III trials adding later-line systemic therapy options are discussed. Clinical recommendations based on the data available are summarized. We conclude that deliberate efforts to include older individuals in future colorectal cancer trials are essential to better guide the management of these patients in this rapidly evolving field.

References
1.
Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17):1731-40. DOI: 10.1056/NEJMoa040694. View

2.
Andre T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A . Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015; 33(35):4176-87. DOI: 10.1200/JCO.2015.63.4238. View

3.
Bosset J, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L . Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355(11):1114-23. DOI: 10.1056/NEJMoa060829. View

4.
Extermann M, Boler I, Reich R, Lyman G, Brown R, DeFelice J . Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2011; 118(13):3377-86. DOI: 10.1002/cncr.26646. View

5.
Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F . Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2016; 3(2):194-201. PMC: 7505121. DOI: 10.1001/jamaoncol.2016.3797. View